MALIGNANT ROLANDIC-SYLVIAN EPILEPSY

The diagnosis, treatment, and outcomes of seven children with a syndrome termed "malignant rolandic-sylvian epilepsy (MRSE)" are described following retrospective chart analyses of 24 patients who were studied with magnetoencephalography (MEG) and intracranial video-EEG (IVEEG) at The Hospital for Sick Children, Toronto, Canada. All had undergone surgical treatment for intractable localization-related epilepsy between 1997 and 2000. The seven children diagnosed with MRSE, ages 6-16 years, had common characteristics: refractory sensorimotor seizures (SMS), frequent frontocentrottemporal EEG spikes, normal MRI, rolandic-sylvian spike source on MEG, and cognitive deficits. Seizures had begun between 1 and 6 years of age, and were refractory to antiepileptic medications for more than 5 years. Subdural ECoG was required to lateralize and localize the epileptic zone before surgery. Cortical excision and multiple subpial transection controlled seizures completely in 3 and almost fully in 4, at 30 months' mean follow-up. Two had a worsening of attentional deficits. Analysis of excised tissue showed neuronal migration disorder in 3 and gliosis in 2. (Otsubo H, Chitoku S, Ochi A et al. Malignant rolandic-sylvian epilepsy in children. Diagnosis, treatment, and outcomes. Neurology August (2 of 2) 2001;57:590-596). (Reprints: Dr H Otsubo, Division of Neurology, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, M5G IX8, Canada).

COMMENT. The term malignant rolandic-sylvian epilepsy (MRSE) has been coined for a subgroup of patients with atypical benign rolandic epilepsy (BRE) and Landau-Kleffner syndrome (LKS) variant, and others with intractable sensorimotor seizures, EEG centrotemporal spikes, and cognitive impairment. MRSE differs from BRE and LKS in seizures that are refractory, secondarily generalized, and occurring in clusters. Intracranial video-EEG, neuropsychological testing, and MEG are important in diagnosis and surgical evaluation and treatment.

EFFECT OF FOOD ON ABSORPTION OF DILANTIN AND MYLAN XR

The effect of a high-fat meal on the absorption of 100-mg Dilantin Kapseals and 100-mg Mylan extended-release phenytoin sodium capsules was determined in a single-dose, two-way crossover study conducted at the University of Florida, Gainesville, FL. Bioavailability of Mylan administered with food was 13% lower than that of Dilantin Kapseals, an effect resulting in a median 37% decrease in plasma phenytoin and subtherapeutic levels in 46% of patients. Simulations of substituting Dilantin for Mylan result in a 15% increase in bioavailability, a median 102% increase in plasma phenytoin and toxic levels in 84% of patients. Food effect studies of bioavailability are important in FDA regulations regarding bioequivalence of phenytoin products. (Wilder BJ, Leppik I, Hietpas TJ et al. Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. Neurology August (2 of 2) 2001;57:582-589). (Reprints: Dr BJ Wilder, Department of Neurology and Neuroscience, University of Florida, 10530 NW 15th Place, Gainesville, FL 32606).

COMMENT. When administering phenytoin products with meals, the observed alterations in bioavailability may cause significant changes in therapeutic efficacy or toxicity. The substitution of Mylan, an extended phenytoin capsule, for Dilantin Kapseals can result in decreased phenytoin serum levels and impaired seizure control. The authors recommendations to prevent unintended alterations in PHT concentrations when switching products include the following:
If a change to Mylan is considered necessary, take 1 hour before meals, not with meals, and monitor levels closely, especially with higher dose and blood levels.

Effect of food on bioavailability of Dilantin Kapseals. Dr Wilder and colleagues at the University of Florida have also examined the effect of food on a single 100 mg dose of Dilantin Kapseals, given 1) after an 8-hour fast and 2) after a high-fat meal, in a nonblinded, randomized, crossover trial. (Cook J, Randinitis E, Wilder BJ. Neurology August (2 of 2) 2001;57:698-700). In 24 healthy adult volunteers, absorption of Dilantin was not significantly different under fasting and fed conditions. It is suggested that Dilantin Kapseals may be administered without regard to meal times, at least in healthy adults.

PAINFUL AURAS IN FOCAL EPILEPSY

The localizing and lateralizing value of painful epileptic auras in 25 patients with focal epilepsy were studied at the Cleveland Clinic, OH. In a group of 604 consecutive cases of focal epilepsies reviewed, 25 had painful auras (4.1%). Age at seizure onset was mainly in childhood (median 7 years, range 1 to 42). Pain was associated with temporal (TLE, 14 cases), frontal (FLE, 6), parieto-occipital (POLE, 2), and periorolateral (PRE, 3) lobe epilepsies. The auras were localized to the abdomen (painful abdominal) in 10 (most with TLE), head and face (painful cephalic) in 11, and extremities (painful somatosensory) in 6. The greatest number of painful auras occurred with TLE, while the greatest frequency was with PRE (10%). Although the number of painful abdominal auras was highest in TLE (6/119, 5%), the frequency was highest in FLE (4/8, 50%). Somatosensory painful auras with PRE were contralateral to the epileptic focus, but with TLE they were sometimes ipsilateral. Painful epileptic auras may resolve after focal cortical resection, which suggests a cortical representation for pain. (Nair DR, Najm I, Bulacio J, Luders H. Painful auras in focal epilepsy. Neurology August (2 of 2) 2001;57:700-702). (Respond: Dr Dileep R Nair, Department of Neurology, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195).

COMMENT. An ictal origin for pain has been described infrequently, originally by Gowers in 1901 and later by Lennox and Cobb in 1933. Among 750 patients reporting auras, 2.8% had painful sensations, vs 6% with numbness and 5.1% paresthesias (Lennox WG. Epilepsy and Related Disorders. Boston, Little, Brown, 1960). In the present series, the greatest number of cases were associated with temporal lobe epilepsy.

GAIT-INDUCED EPILEPSY

A 3 year-old boy with gait-induced seizures is reported from University of Navarra, Pamplona, Spain. His father and grandmother had primary generalized epilepsy. He sat late at 12 months and walked late at 26 months. After recovery from a febrile illness at 2 years 10 months, he developed jerking of the left lower limb, impairing is ability to walk. EEG showed right parietooccipital spikes, and generalized S/W in sleep. While walking, slow S/W rhythmic discharges at C4 correlated with jerking of the left leg. At rest, the discharges resolved. MRI was suggestive of polymicrogyria in right frontal area. Ictal SPECT showed hyperperfusion on the right side with walking. After valproate therapy for 3 weeks, jerking decreased and walking ability improved. (Iriate J, Sanchez-Carpintero R, Schlumberger E et al. Gait epilepsy. A case report of gait-induced seizures. Epilepsia August 2001;42:1087-1090). (Repints: Dr Jorge Iriate, Department of Neurology, Clinica Universitaria, University of Navarra, Pio XII 36, Pamplona 31008, Navarra, Spain).